[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPWO2019160057A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019160057A5
JPWO2019160057A5 JP2020500562A JP2020500562A JPWO2019160057A5 JP WO2019160057 A5 JPWO2019160057 A5 JP WO2019160057A5 JP 2020500562 A JP2020500562 A JP 2020500562A JP 2020500562 A JP2020500562 A JP 2020500562A JP WO2019160057 A5 JPWO2019160057 A5 JP WO2019160057A5
Authority
JP
Japan
Prior art keywords
bone
disease
inflammatory disease
prophylactic
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020500562A
Other languages
English (en)
Other versions
JP7548669B2 (ja
JPWO2019160057A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/005415 external-priority patent/WO2019160057A1/ja
Publication of JPWO2019160057A1 publication Critical patent/JPWO2019160057A1/ja
Publication of JPWO2019160057A5 publication Critical patent/JPWO2019160057A5/ja
Application granted granted Critical
Publication of JP7548669B2 publication Critical patent/JP7548669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (20)

  1. 下記式(1)で表される化合物又はその薬理学的に許容される塩を有効成分として含有する、炎症性疾患若しくは骨疾患の予防又は治療剤。
    Figure 2019160057000001
    [式(1)中、Xは、水素原子、ハロゲン原子又は置換されていてもよい炭素数1~10のアルキル基を表し、Rは、置換されていてもよい炭素数1~10のアルキル基、置換されていてもよい炭素数1~10のアルケニル基又は置換されていてもよい炭素数6~14のアリール基を表し、1以上の水素原子は重水素原子に置換されていてもよい。]
  2. 下記式(2)で表される化合物又はその薬理学的に許容される塩を有効成分として含有する、請求項1に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
    Figure 2019160057000002
  3. 式(2)中の1以上の水素原子が重水素原子に置換されている、請求項2に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  4. 前記炎症性疾患が、潰瘍性大腸炎、クローン病、関節リウマチ、強直性脊椎炎、インスリン依存性糖尿病、アジソン病、グッドパスチャー症候群、IgA腎症、間質性腎炎、シェーグレン症候群、自己免疫性膵炎、乾癬、アトピー性皮膚炎、肺炎、慢性気管支炎、気管支喘息、全身性紅斑性狼瘡(SLE)、強皮症又はせん妄であり、前記骨疾患が、骨粗鬆症、溶骨性骨転移又は骨パジェット病である、請求項1~3のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  5. 下記式(3)で表される化合物及びその薬理学的に許容される塩を実質的に含まない、請求項1~のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
    Figure 2019160057000003
    [式(3)中、Xは、水素原子、ハロゲン原子又は置換されていてもよい炭素数1~10のアルキル基を表し、Rは、置換されていてもよい炭素数1~10のアルキル基、置換されていてもよい炭素数1~10のアルケニル基又は置換されていてもよい炭素数6~14のアリール基を表す。]
  6. 下記式(4)で表される化合物及びその薬理学的に許容される塩を実質的に含まない、請求項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
    Figure 2019160057000004
  7. 式(1)で表される化合物又はその薬理学的に許容される塩がR-ケタミンである、請求項1~6のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  8. 式(3)で表される化合物又はその薬理学的に許容される塩がS-ケタミンである、請求項5~7のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  9. 式(3)で表される化合物を0.15モル%以下含む、請求項5~8のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  10. 式(3)の化合物を含まない、請求項5~8のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  11. 式(4)の化合物を0.15モル%以下含む、請求項6~8のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  12. 式(4)の化合物を含まない、請求項6~8のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
  13. 請求項1~12のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤と、薬理学的に許容される担体とを含有する、炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  14. 経口投与、経鼻腔投与、静脈内投与、皮下投与又は筋肉内投与用に製剤化される、請求項13に記載の炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  15. 液剤、溶液、懸濁液、粉剤、錠剤、コーティング錠、カプセル剤、トローチ剤、クリーム剤、坐剤、ゲル剤、パッチ剤、リニメント剤又はエアロゾル剤の形態である、請求項13に記載の炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  16. 炎症性疾患若しくは骨疾患を有する対象の治療用組成物を治療上有効量含む、請求項13に記載の炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  17. 治療上有効量が約0.01/人/日~約1000mg/人/日である、請求項16に記載の炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  18. 治療上有効量が約0.1/人/日~約500mg/人/日である、請求項16に記載の炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  19. 治療上有効量が約0.1/人/日~約100mg/人/日である、請求項16に記載の炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
  20. 対象における炎症性疾患若しくは骨疾患の予防又は治療用医薬の製造で使用するための、請求項1~12のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
JP2020500562A 2018-02-15 2019-02-14 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 Active JP7548669B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018025170 2018-02-15
JP2018025170 2018-02-15
JP2018121858 2018-06-27
JP2018121858 2018-06-27
PCT/JP2019/005415 WO2019160057A1 (ja) 2018-02-15 2019-02-14 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2019160057A1 JPWO2019160057A1 (ja) 2021-02-04
JPWO2019160057A5 true JPWO2019160057A5 (ja) 2022-02-24
JP7548669B2 JP7548669B2 (ja) 2024-09-10

Family

ID=67618723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500562A Active JP7548669B2 (ja) 2018-02-15 2019-02-14 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物

Country Status (7)

Country Link
US (1) US11980595B2 (ja)
EP (1) EP3753557A4 (ja)
JP (1) JP7548669B2 (ja)
CN (2) CN118453559A (ja)
BR (1) BR112020016500A2 (ja)
TW (1) TW201936567A (ja)
WO (1) WO2019160057A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872841B2 (en) 2013-09-13 2018-01-23 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
IL294202A (en) 2019-12-26 2022-08-01 Gilgamesh Pharmaceuticals Inc History of arylcyclohexylamine and their use in the treatment of psychiatric disorders
EP4084791A1 (en) 2020-02-18 2022-11-09 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
CN118647595A (zh) 2021-10-12 2024-09-13 感知神经科学公司 R-氯胺酮盐及其使用方法
WO2023178039A1 (en) 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4670459A (en) 1984-10-03 1987-06-02 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
EP1257648B2 (en) 2000-02-23 2016-09-14 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
BRPI0002693B8 (pt) 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1567145B1 (en) 2002-11-18 2009-06-03 Yaupon Therapeutics, Inc. Analgesic uses of (s)-norketamine
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US7928132B2 (en) 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US20090246255A1 (en) 2005-09-28 2009-10-01 Thomas Meyer Pharmaceutical Compositions for the Treatment of Inner Ear Disorders
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
EP2139848A1 (en) 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
AU2013305580A1 (en) 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
US20140275276A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
WO2014169272A1 (en) 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
US9872841B2 (en) 2013-09-13 2018-01-23 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
WO2015108985A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
EP3130582B8 (en) 2014-04-29 2019-01-02 The Catholic University of Korea Industry-Academic Cooperation Foundation Compound having immune disease treatment effect and use thereof
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
RS65411B1 (sr) 2014-11-04 2024-05-31 Acadia Pharm Inc Jedinjenja neuroatenuirajućeg norketamina i metodi
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
CA2989319C (en) 2015-06-19 2019-02-05 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for anesthesiological applications
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2017165877A1 (en) 2016-03-25 2017-09-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders
CN108884019A (zh) 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
JP6327591B2 (ja) 2016-08-12 2018-05-23 マツダ株式会社 ディーゼルエンジンの制御方法及び制御システム
US20200261442A1 (en) 2016-08-26 2020-08-20 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CN109890371A (zh) 2016-08-26 2019-06-14 斯瑞尼瓦萨饶·韦帕切杜 组合物及其方法
US20180177743A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain using racemic mixture of s-ketamine and r-ketamine
CN110325231B (zh) 2016-12-27 2020-10-02 阿克申医药科技有限公司 用于注射药物的设备和方法
JP6926383B2 (ja) 2017-01-31 2021-08-25 日本製紙クレシア株式会社 吸収性補助パッド及びその使用方法
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
BR112019024802A2 (pt) 2017-05-25 2020-07-21 Glytech Llc. terapia combinada para transtornos neuropsiquiátricos responsivos ao antagonista de nmdar
EP3641742A2 (en) 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
TW201919595A (zh) 2017-09-27 2019-06-01 國立大學法人千葉大學 作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
CN111836798B (zh) 2018-01-10 2022-04-15 凯瑞康宁生物工程(武汉)有限公司 氯胺酮的前药、其组合物和用途
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
WO2019169165A1 (en) 2018-02-28 2019-09-06 Novocine Therapeutics, Llc Ketamine and ketamine-related compounds for the treatment of neurological disorders
EP3761970A4 (en) 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
GB201809976D0 (en) 2018-06-18 2018-08-01 Neurocentrx Pharma Ltd Novel formulations
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US20210378989A1 (en) 2018-10-11 2021-12-09 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3903775A4 (en) 2018-12-27 2022-10-12 National University Corporation Chiba University R-KETAMINE AND ITS DERIVATIVE USEFUL AS A PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST A NEURODEVELOPMENTAL DISORDER
WO2020143762A1 (en) 2019-01-11 2020-07-16 Alar Pharmaceuticals Inc. Ketamine pamoate and use thereof
WO2020198039A1 (en) 2019-03-23 2020-10-01 Sermone Sandra Ketamine for treatment of sensory processing deficits
WO2020212510A1 (en) 2019-04-16 2020-10-22 Janssen Pharmaceutica Nv Synthetic methods of preparing esketamine
WO2020232274A1 (en) 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
AU2020324432A1 (en) 2019-08-05 2021-10-07 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
US11007200B2 (en) 2019-08-21 2021-05-18 MediSynergics, LLC Cycloalkyl-diamines for the treatment of pain
MX2022006596A (es) 2019-12-20 2022-07-05 Alar Pharmaceuticals Inc Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina.
IL294202A (en) 2019-12-26 2022-08-01 Gilgamesh Pharmaceuticals Inc History of arylcyclohexylamine and their use in the treatment of psychiatric disorders
US20230063459A1 (en) 2019-12-30 2023-03-02 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US20230049897A1 (en) 2019-12-30 2023-02-16 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
WO2021150985A1 (en) 2020-01-22 2021-07-29 Seelos Therapeutics, Inc. Reducing side effects of nmda antagonists
EP4125836A1 (en) 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
JP2023520912A (ja) 2020-04-07 2023-05-22 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
WO2021231905A1 (en) 2020-05-15 2021-11-18 The University Of Kansas Ketamine treatment for amyotrophic lateral sclerosis
WO2021252971A2 (en) 2020-06-12 2021-12-16 Bexson Biomedical, Inc. Systems and devices for controlled drug delivery
WO2021255737A1 (en) 2020-06-17 2021-12-23 Spirify Pharma Inc. Hydroxynorketamine analogues, compositions comprising same and methods of use thereof

Similar Documents

Publication Publication Date Title
JPWO2019160057A5 (ja)
JP4742026B2 (ja) ロフルミラストの新規の製造方法
JP2013535437A5 (ja)
AU2014298051B2 (en) Novel quinazolinones as bromodomain inhibitors
JP2017510624A5 (ja)
JP2012532112A5 (ja)
JP2018535967A5 (ja)
RU2012137180A (ru) Гетероциклические ингибиторы гистаминовых рецепторов для лечения заболеваний
WO2017040993A4 (en) Small molecule inhibitors of dyrk1a and uses thereof
JP2013536825A (ja) ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
JP2008531537A5 (ja)
JP2019515884A5 (ja)
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
JP2013515074A5 (ja)
JP2014503533A5 (ja)
JP2014516942A5 (ja)
JP2017511339A5 (ja)
JP2018537513A5 (ja)
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
JP2015505564A5 (ja)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP2019515908A5 (ja)
JP2019520344A5 (ja)
RU2014119711A (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx